# A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

> **NCT02368665** · PHASE3 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 180 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Amlodipine 5mg
- **DRUG:** Amlodipine 5mg, Candesartan cilexetil 16mg
- **DRUG:** Amlodipine 10mg, Candesartan cilexetil 16mg

## Key facts

- **NCT ID:** NCT02368665
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368665, "A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02368665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*